Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue

Title:Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue

Volume: 20 Issue: 42

Author(s): Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu

Affiliation:

Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.

Abstract: Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.

Cite this article as:

Cavalcante Ludimila, Kelsen P. David and Yu H. Kenneth, Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140826154724